![](/wp-content/uploads/2018/10/xPLZOlqQTYq3WYxWaT90.png)
$599
No Sotagliflozin CRL Clarity; Sanofi Q1 ’19 Earnings Update
Sanofi hosted its Q1 ’19 earnings call but only briefly discussed its diabetes business including the recent sotagliflozin T1DM CRL. Below, FENIX provides highlights and insights from the call.